Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05560659 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy

Study acronym: POPSTAR II
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 11, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: May 2025 to May 2026
    • Study completion date: May 2026 to May 2027
    • Eligibility criteria shortened, about 38 words
    v9
  2. Study sites: 2 to 3v8
  3. Study sites: 1 to 2v7
  4. Eligibility criteria shortened, about 10 wordsv6
  5. Eligibility criteria shortened, about 4 wordsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 2023 to Dec 14, 2023
    v4
  2. Start date: Sep 2023 to Nov 2023v3
  3. Start date: Nov 2022 to Sep 2023v2 Show 5 more changesShow less
    • Primary completion date: Nov 2024 to May 2025
    • Study completion date: Nov 2025 to May 2026
    • Eligibility criteria shortened, about 48 words
    • Secondary endpoints: 8 to 9
    • Study description expanded, about 5 words
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.
Trial Details
NCT Number NCT05560659
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Collaborators: Varian Medical Systems
Conditions
(from sponsor)		 Oligometastatic Prostate Cancer
Enrollment 92 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov